TITLE

Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain

AUTHOR(S)
Charest, Gabriel; Sanche, Léon; Fortin, David; Mathieu, David; Paquette, Benoit
PUB. DATE
December 2013
SOURCE
Journal of Neuro-Oncology;Dec2013, Vol. 115 Issue 3, p365
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Treatment of glioblastoma with platinum compounds modestly improves progression-free survival and may cause toxic effects which prevent use at higher dose that would otherwise improve the antineoplastic effect. To reduce toxicity, we propose to encapsulate the platinum drug in a liposome. We have also tested three methods of drug administration (intra-venous, intra-arterial and intra-arterial combined with blood brain barrier disruption) to determine which one optimizes the tumor cell uptake, limits the toxicity and delivers the best concomitance effect with radiotherapy. Cisplatin, oxaliplatin, their respective liposomal formulations, Lipoplatin™ and Lipoxal™, and carboplatin were assessed in F98 glioma, orthotopically implanted in Fischer rats. We found that the modest accumulation of drugs in tumor cells after intra-venous injection was significantly improved when the intra-arterial route was used and further increased after the transient opening of the blood brain barrier with mannitol. The liposomal formulations have largely reduced the toxicity and have allowed a better exploitation of the anti-cancer activity of platinum agent. Although the liposomes Lipoplatin™ and Lipoxal™ have shown a similar ability to that of carboplatin, to accumulate in brain tumors, the highest additive effect with radiotherapy was obtained with carboplatin. We conclude that the intra-arterial infusion of carboplatin or Lipoxal™ in concomitance with radiation therapy leads to the best tumor control as measured by an increase of mean survival time in Fischer rats implanted with the F98 glioma with a benefit in survival time of 13.4 and 6.5 days respectively compared to intra-venous.
ACCESSION #
91933385

 

Related Articles

  • Constitutive Expression of MAP Kinase Phosphatase-1 Confers Multi-drug Resistance in Human Glioblastoma Cells. Hana Yu; Junseong Park; Jungsul Lee; Kyungsun Choi; Chulhee Choi // Cancer Research & Treatment;Sep2012, Vol. 44 Issue 3, p195 

    Purpose Current treatment of glioblastoma after surgery consists of a combination of fractionated radiotherapy and temozolomide. However, it is difficult to completely remove glioblastoma because it has uncertain boundaries with surrounding tissues. Moreover, combination therapy is not always...

  • Characterization of the distribution, retention, and efficacy of internal radiation of Re-lipid nanocapsules in an immunocompromised human glioblastoma model. Cikankowitz, Annabelle; Clavreul, Anne; Tétaud, Clément; Lemaire, Laurent; Rousseau, Audrey; Lepareur, Nicolas; Dabli, Djamel; Bouchet, Francis; Garcion, Emmanuel; Menei, Philippe; Couturier, Olivier; Hindré, François // Journal of Neuro-Oncology;Jan2017, Vol. 131 Issue 1, p49 

    Internal radiation strategies hold great promise for glioblastoma (GB) therapy. We previously developed a nanovectorized radiotherapy that consists of lipid nanocapsules loaded with a lipophilic complex of Rhenium-188 (LNCRe-SSS). This approach resulted in an 83 % cure rate in the 9L rat glioma...

  • Single oral dose toxicity test of polycalcium, a mixed composition of polycan and calcium lactate-gluconate 1:9 (G/G) in SD rat. Joo-Wan Kim; Jae-Suk Choi; Yu-Mi Ha; In Soon Choi; Ki-Young Kim; Hyung-rae Cho; Chae-Hun Rha; Sae-Kwang Ku // Pakistan Journal of Pharmaceutical Sciences;Nov2013, Vol. 26 Issue 6, p1141 

    The object of this study was to obtain acute oral toxicity information of Polycalcium, a mixed composition of Polycan and Calcium lactate-gluconate 1:9 {gig), in Sprague-Dawely (SD) rats. In order to investigate the toxicity and identify target organs, Polycalcium were once orally administered...

  • Erratum to: Role of Methamphetamine on Glioblastoma Cytotoxicity Induced by Doxorubicin and Methotrexate. Capelôa, Tânia; Caramelo, Francisco; Fontes-Ribeiro, Carlos; Gomes, Célia; Silva, Ana // Neurotoxicity Research;Oct2014, Vol. 26 Issue 3, p228 

    No abstract available.

  • Bevacizumab in Recurrent Glioblastoma: Efficacy Benchmarks and Safety in Different Doses, Combinations, Time and Situations. Gil-Gil, Miguel J.; Barroso, Carles Mesía; Escuer, Jordi Bruna // Cancer & Chemotherapy Reviews;Apr-Jun2014, Vol. 9 Issue 2, p51 

    Glioblastoma or grade IV glioma is the most common primary brain tumor in adults. With standard treatment, median overall survival is only 14-15 months and less than 10% of patients will survive five years after diagnosis. There is no standard treatment in recurrent glioblastoma and overall...

  • Combination of RGD Compound and Low-Dose Paclitaxel Induces Apoptosis in Human Glioblastoma Cells. Ming-Wei Chang; Jem-Mau Lo; Hsueh-Fen Juan; Hsin-Yi Chang; Chun-Yu Chuang // PLoS ONE;May2012, Vol. 7 Issue 5, p1 

    Background: Integrins are a family of transmembrane adhesion proteins that mediate cell adhesion and intracellular signaling. Integrin-αvβ3 is expressed on the surface of human glioblastoma cells, and can be further induced by chemical stress. The Arg-Gly-Asp (RGD) motif-containing...

  • Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme? Gallo, Chiara; Buonerba, Carlo; Lorenzo, Giuseppe; Romeo, Valeria; Placido, Sabino; Marinelli, Alfredo // Journal of Neuro-Oncology;Nov2010, Vol. 100 Issue 2, p311 

    Glioblastoma multiforme (GBM), the highest grade malignant glioma, is associated with a grim prognosis-median overall survival is in the range 12-15 months, despite optimum treatment. Surgery to the maximum possible extent, external beam radiotherapy, and systemic temozolomide chemotherapy are...

  • TSPO as a target for glioblastoma therapeutics. Werry, Eryn L.; Barron, Melissa L.; Kassiou, Michael // Biochemical Society Transactions;8/1/2015, Vol. 43 Issue 4, p531 

    The translocator protein (TSPO) is an 18-kDa five-transmembrane protein, which is primarily found in the outer mitochondrial membrane. Levels of this protein are up-regulated in the most aggressive and common glioma, glioblastoma multiforme (GM). Levels of TSPO also correlate with GM clinical...

  • Analysis of cellular and molecular antitumor effects upon inhibition of SATB1 in glioblastoma cells. Frömberg, Anja; Rabe, Michael; Oppermann, Henry; Gaunitz, Frank; Aigner, Achim // BMC Cancer;1/3/2017, Vol. 17, p1 

    Background: The Special AT-rich Sequence Binding Protein 1 (SATB1) regulates the expression of many genes by acting as a global chromatin organizer. While in many tumor entities SATB1 overexpression has been observed and connected to pro-tumorigenic processes, somewhat contradictory...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics